| Detailed information |
|---|
| CancerLivER ID | 2568 |
| Biomarker | VIM or Vimentin |
| Biomarker Name/Symbol (given in Publication) | VIM or Vimentin |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for HCC metastasis; but not validated on independent dataset |
| Experimental Condition | Primary v/s metastasis; significantly associated with HCC metastasis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Upegulated in HCC |
| Level of significance | p< 0.01 |
| Source | Tissue |
| PMID | 14647434 |
| Type of Biomarker | Prognostic |
| Pathway | Adhesion, cell motility and invasiveness, ECM signaling,classical complement activation pathway |
| Cohort | 200 primary HCCs and 60 pairs of primary and matched metastatic HCC samples ((including 31 intrahepatic and 29 extrahepatic metastases). |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | HCC |
| Year of Publication | 2003 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT00987766 |